Scientists hunt for clues to rare CAR-T side effects in myeloma
NCT ID NCT07665307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. The goal is to better understand these side effects and improve how doctors monitor and treat them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ciltacabtagene autoleucel (cilta-cel)
What this could lead to
If successful, this study could point toward better ways to predict, monitor, and manage rare but serious side effects of CAR-T therapy, making treatment safer for future patients.
What could go wrong
This is a small, early observational study (30 participants) that does not test a new treatment. It may not find clear biomarkers, and results may not apply to all patients or CAR-T products.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
-
Mount Sinai
New York, New York, 10029, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
UCSF Medical Center
San Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••